Antibody drug conjugate

What is an ADC? Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized. https://www.creative-biolabs.com/adc/services.htm

All chemical linkers are of >95% purity and they are the basic building blocks for a successful ADC. Linkers facilitate the conjugation of ADC toxins to antibodies and in the meantime, they also dictate the release mechanism of an ADC. Proper linker selection will not only ease the process of obtaining the conjugate but also help enhance the chemical and serum stability of the ADC, such as val cit pab. https://www.creative-biolabs.com/adc/classify-adc-linkers-7.htm

ADC toxins target crucial intracellular pathways to induce cell death and they can be over 1000-fold more potent than chemo therapeutic agents. A large selection of ADC toxins range from common auristatins, maytansinoids, calicheamicins to more innovative toxins such as amatoxins, polyketomycin…. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

Ipatasertib shows a powerful inhibition of all protein kinase B (Akt) isoforms but a weak suppression towards other members of the protein kinase family. Treatments of both tumor xenograft mouse models and human cancer cell lines with ipatasertib showed a significant suppression of Akt signaling, leading to a disruption in cell cycle progression and reduced cancer cell viability. https://www.creative-biolabs.com/adc/ipatasertib-akt-inhibitor.htm

Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in antibody design services. One downside in using the endogenous amino acids for ADC development is a heavily dispersed DAR conjugation caused by the non-uniform distribution of the...

ADEPT antibody is regarded as an “indirect targeting method” that involves two steps. Firstly, a non-toxic antibody–enzyme fusion protein is applied to the tumor matrix and binds to the tumor cells via tumor-specific antigen recognized by the antibody. Upon binding, an inert small-molecule prodrug is then given. The prodrug is the substrate for the enzyme portion of the antibody–enzyme fusion that is anchored to the tumor surface. Once the prodrug reaches the enzyme, an active cytotoxic...

The target-oriented high-quality ADC custom products are suitable for tasks such as proof-of-concept, target validation, as well as control to provide comparison in efficacy for new ADC development projects. https://www.creative-biolabs.com/adc/target-list-customized-adcs-1.htm

As the new generation of immunotherapy, ADCs are meticulously constituted bio-macromolecules with high potential in the treatment of cancer and various other diseases. The information gathered from in vitro analysis provides a guideline for ADC optimization and the downstream in vivo ADC assessment. https://www.creative-biolabs.com/adc/adc-in-vitro-analysis.htm

To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites. One downside in using the endogenous amino acids for ADC development is a heavily dispersed conjugation of DAR caused by the non-uniform distribution of the conjugation sites, especially in the case of Lysine-based conjugations....

During the development of effective and safe antibody-drug conjugates some technical issues arose. The generation of an appropriate chemical linkers between the monoclonal antibody and the cytotoxic drug turns out to be a major difficulty. This is due to the complex synthesis of linker chemistry. On the other hand, the design of types of linkers is highly dependent on the target cells biology, the antibody characteristics, and the molecule structure of the drug. With the development of ADCs...

A suitable payload drug will be selected and coupled with a linker with desired releasing mechanism in “DrugLnk” to assemble the “chemical warhead” for an ADC, which is subsequently conjugated with the desired antibody using Antibody Design and Conjugation services. Certain modification or engineering of the selected antibody is also carried out in antibody conjugation service module. https://www.creative-biolabs.com/adc/antibody-drug-conjugate-adc.htm

As one major component of antibody conjugates, the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm

Antibody-drug conjugates (ADCs) inherit high specificity and affinity towards well-defined targets and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature. Therefore, ADCs have raised great attention in antibody chemistry filed. https://www.creative-biolabs.com/adc/antibody-drug-conjugate-adc.htm

Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan AKT inhibitor. It was initially derived during the screening and optimization process of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds. https://www.creative-biolabs.com/adc/ipatasertib-akt-inhibitor.htm

Compared with conventional therapeutic treatment, monoclonal immunotherapies are highly advantageous due to their high specificity and affinity towards well-defined targets and so are antibody-drug conjugates (ADCs). Moreover, consisting of the monoclonal antibody, a cytotoxic payload, and a molecular linker, ADC expands the therapeutic window of the conjugated drugs (payloads), which is usually highly toxic and diverse in their biochemical nature....

These high-quality custom ADCs are suitable for tasks such as proof-of-concept, target validation, as well as control to provide comparison in efficacy for new ADC development projects. The ADC custom products are target-oriented. https://www.creative-biolabs.com/adc/target-list-customized-adcs-1.htm

Mass spectrometry techniques can be used to evaluate the stability of the linker, analyze free drugs, metabolites, different DAR components, and relative proportions. LC/MS, such as HIC or RP-HPLC coupled with mass spectrometry, has been used for ADC drug structure and composition analysis, to evaluate the stability of ADC linkers, to analyze DAR and coupling sites, and to determine the relative DAR components. Proportion and so on. One of the challenges of mass spectrometry technology is...

Antibody-drug conjugates (ADCs) are a class of drugs that conjugate a monoclonal antibody to a different number of small molecule cytotoxins (effector molecules) by chemical linkers. This novel drug combines the high specificity of monoclonal antibodies with the high activity of small molecule toxins. Chromatographic analysis of antibody-conjugated drugs and their enzymatic products can obtain important information such as the number and location of coupling sites, free drug content, and...

For the conjugated antibody ELISA, when a drug-resistant antibody is used as a capture agent, it may not be possible to uniformly measure ADC drug with different drug loadings, and with anti drug conjugate as detection reagents, it may not be possible to obtain a ratio proportional to the number of drug molecules. https://www.creative-biolabs.com/adc/services.htm

Immunoassays include detection of binding of antibody-conjugated drugs to target proteins; quantitative ADC analysis; evaluation of stability of linkers and drugs; detection of binding to FcγR and evaluation of immunogenicity. These assays are important for understanding the potency, pharmacokinetics, and safety of antibody-conjugated drugs. Among them, enzyme-linked immunosorbent assays are often used to evaluate the concentration of antibody-drug conjugates and their binding to...